A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters시리아 햄스터의 바이러스 부담과 질병 중증도를 감소시키는 강력한 SARS-CoV-2 중화 인간 단일클론 항체Immunology Published on 2020-12-182022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, [키워드] antibody approach burden caused Clinical management clone contributed coronavirus COVID COVID-19 COVID-19 patients deaths demonstrated Dexamethasone disease disease severity Efficacy hamster Histopathology Human Human monoclonal antibody immunopathological in vitro infiltration Lungs monoclonal Ab monocyte morbidity neutralized pandemic potent Receptor binding domain reduced reducing reduction Remdesivir SARS-CoV-2 significantly specificity Spike protein the SARS-CoV-2 therapeutic antibodies therapy Treatment Viral load virus yeast [DOI] 10.3389/fimmu.2020.614256 PMC 바로가기 [Article Type] Immunology
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive SpikeReport Published on 2020-12-182022-10-28 Journal: Science (New York, N.y.) [Category] COVID-19, [키워드] ACE2 acute respiratory syndrome affinity airway epithelia angiotensin-converting enzyme 2 Anti-spike antibody Bacteria bind binding cells coronavirus cryo-EM disrupt group host cell host cell receptor inaccessible inactive Interaction intravenously mammalian cell maturation Microscopy multivalent nanobodies nanobody neutralization neutralize potent produced Protein Receptor binding domain SARS-CoV-2 SARS-COV-2 infection Science screened selected spike stability synthetic nanobody the spike protein therapeutic Treatment trivalent virus yeast [DOI] 10.1126/science.abe3255 PMC 바로가기 [Article Type] Report
Nonstructural Protein 1 of SARS-CoV-2 Is a Potent Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNASARS-CoV-2의 비구조 단백질 1은 숙주 단백질 합성 기계를 바이러스 RNA로 리디렉션하는 강력한 병원성 인자입니다Article Published on 2020-12-172022-09-11 Journal: Molecular Cell [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] 40S Alter Cell cell viability cellular cellular transcriptome complex COVID-19 pandemic cryo cryo-EM cryo-EM structure Differential expression analysis Factor Host human lung Impact inhibit mechanism mechanisms mRNA nonstructural protein 1 nsp1 paralysis pathogenicity potent protein synthesis ribosome RNA SARS-CoV-2 suppress synthesis the cells Transcriptome transcriptome alteration translation translation inhibition mechanism. viability Viral Viral proteins virus [DOI] 10.1016/j.molcel.2020.10.034 PMC 바로가기 [Article Type] Article
Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based DerivativesPharmacology Published on 2020-12-142022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] anti-viral activity antiviral properties assays Compound coronavirus Coronaviruses COVID-19 derivative end point examined FIPV gastroenteritis greater HCoV-229E HCoV-OC43 host cell factors human coronavirus OC43 human coronaviruses inhibit SARS-CoV-2 inhibited inhibition inhibitor inhibitors log magnitude ouabain potent Replication SARS-CoV-2 steroid tested therapeutic Treatment tylophorine Viral RNA virus [DOI] 10.3389/fphar.2020.606097 PMC 바로가기 [Article Type] Pharmacology
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2Article Published on 2020-12-042022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] activity alleviate Anti-inflammatory anti-inflammatory drug antimicrobial drugs Antiviral antiviral activity approach Azithromycin binding Combination coronavirus 2 COVID-19 COVID-19 pandemic COVID-19 patients disease drug Drug discovery Drug repurposing drugs Evidence food Hydrogen bond impair in vitro Interaction Ligand MERS-CoV Middle East niclosamide nitazoxanide PDB peptide Piroxicam potent protease provided reduce Replication reported respiratory respiratory symptoms SARS-CoV-2 SARS-CoV-2 replication spike glycoprotein tested Therapeutic benefit Virtual screening [DOI] 10.3390/ph13120443 PMC 바로가기 [Article Type] Article
Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19Discussion Published on 2020-12-012022-10-05 Journal: SLAS discovery : advancing life sciences R & D [Category] SARS, 신약개발, [키워드] 3D structure ACE2 ACE2-B0AT1 addressed adjuvant Amino acid angiotensin-converting enzyme 2 bind caused cells Course COVID-19 COVID-19 disease docked drug Drug discovery effective global pandemic health emergency indications Infection Interaction International involved membrane protein nimesulide Occurrence physical plasma membrane potent receptor repurposing responsible SARS-CoV-2 SARS-CoV-2 biology Scientific community shown SLC6A19 Symptoms target cells tested the SARS-CoV-2 Transport treat Treatment Trial Vaccine viral entry Viral protein virus WHO World Health Organization [DOI] 10.1177/2472555220934421 [Article Type] Discussion
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2SARS-CoV-2에 대한 강력하고 안전한 항바이러스 치료 후보의 식별Immunology Published on 2020-11-252022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 신약개발, 치료제, [키워드] activities Against amlodipine amlodipine besylate anti-SARS-CoV-2 Antiviral arbidol hydrochloride candidate Cell Cell fusion Combination Compound Concentration coronavirus COVID-19 COVID-19 infection COVID-19 infections COVID-19 pandemic death dronedarone dronedarone hydrochloride drug effective Effectiveness experiments FIVE HCl help human coronavirus Hydroxychloroquine identification identify identifying inhibit inhibiting mefloquine monensin monensin sodium monensin sodium salt Mortality OC43 pandemic performed potent Prevent Replication reported SARS-CoV-2 SARS-CoV-2 S SARS-CoV-2 S protein screened sertraline sertraline HCl severe disease sodium therapeutic agent therapeutic agents therapeutic option therapeutic window therapy thioridazine thioridazine hydrochloride tilorone treat US Food and Drug Administration-approved compounds virus vortioxetine [DOI] 10.3389/fimmu.2020.586572 PMC 바로가기 [Article Type] Immunology
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2SARS-CoV-2에 대해 설계된 단백질 나노입자 백신에 의한 강력한 중화 항체 반응의 유도Article Published on 2020-11-252022-09-12 Journal: Cell [Category] Fulltext, SARS, 비임상, 진단, [키워드] antibody Antibody Response Antigen cGMP clinical trial computational protein design convalescent displaying domain ectodomain effective effort elicit elicited Epitopes highlight human sera immunogen immunogenic induce lower dose mice mutations nanoparticle Neutralizing antibody response Neutralizing antibody titer non-overlapping epitope platform potent Protective protective antibody response Protein RBD RBDs Receptor-binding domain Respiratory disease response risk robust Safe SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 spike SARS-CoV-2 vaccine SARS-CoV-2-RBD stability structure-based design susceptible the RBD the SARS-CoV-2 trimer utility Vaccine vaccine candidate vaccine for COVID-19 virus wall [DOI] 10.1016/j.cell.2020.10.043 PMC 바로가기 [Article Type] Article
Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory responseSARS-CoV-2 배출 기간 및 염증 반응의 강도를 결정하는 항바이러스 요법의 효능 및 시기Article Published on 2020-11-202022-09-11 Journal: Science Advances [Category] SARS, 진단, 치료제, [키워드] Affect antiviral therapies antiviral therapy AUC cellular Clinical severity clinical trial clinical trials COVID-19 COVID-19 pandemic decrease determinant develop dosed driven by drug drug resistance early treatment immune response Immunotherapy in vivo Infection Inflammatory response intensity mathematical Mathematical models Neutralizing antibodies performed potency potent predict Predictive presymptomatic Remdesivir SARS-CoV-2 selinexor Support Symptom therapeutic approaches therapy Treatment Viral viral dynamics Viral load viral loads [DOI] 10.1126/sciadv.abc7112 PMC 바로가기 [Article Type] Article
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeysArticle Published on 2020-11-132022-10-04 Journal: Nature Communications [Category] SARS, 변종, 신약개발, 치료제, [키워드] ACE2 ADE angiotensin-converting enzyme 2 antibodies antibody Antibody-dependent enhancement Antiviral binding block characterization convalescent patient COVID-19 disrupting eliminated Fc region FcγRIIb Infection Interaction interfere Intervention LALA mAb monoclonal antibody Mutation Neutralizing activity neutralizing antibody non-human primates potent prevented Prophylactic prophylactic treatment RBD receptor Receptor binding domain Rhesus monkey Rhesus monkeys SARS-CoV-2 SARS-CoV-2 spike single dose therapeutic activity therapeutic effect therapeutic efficacy Therapeutic treatment Translational immunology Treatment [DOI] 10.1038/s41467-020-19568-1 PMC 바로가기 [Article Type] Article